Clinical trial
Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer
NCT00045188 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00045188 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Metastatic Breast Cancer |
| Official title | Phase II Trial of STI571 in Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | Aug 1, 2002 |
| Primary completion | Jul 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: